{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:35:16Z","timestamp":1791891316863,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.tmrv.2006.08.002","type":"journal-article","created":{"date-parts":[[2006,12,14]],"date-time":"2006-12-14T12:10:57Z","timestamp":1166098257000},"page":"37-48","source":"Crossref","is-referenced-by-count":160,"title":["Anticoagulants and Their Reversal"],"prefix":"10.1016","volume":"21","author":[{"given":"Sam","family":"Schulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick R.","family":"Bijsterveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2006.08.002_bib1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archinte.166.8.853","article-title":"Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding","volume":"166","author":"Douketis","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib4","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Levine","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.tmrv.2006.08.002_bib5","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.tmrv.2006.08.002_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1011237019082","article-title":"Anaphylactoid reactions to vitamin K","volume":"11","author":"Fiore","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.tmrv.2006.08.002_bib7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(00)03125-1","article-title":"Treatment of warfarin-associated coagulopathy with oral vitamin K: A randomised controlled trial","volume":"356","author":"Crowther","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2006.08.002_bib8","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2005.09.058","article-title":"The risk of hemorrhage among patients with warfarin-associated coagulopathy","volume":"47","author":"Garcia","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tmrv.2006.08.002_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1055\/s-0037-1613443","article-title":"Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin","volume":"89","author":"Yasaka","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2004.04972.x","article-title":"Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant","volume":"126","author":"O'Shaughnessy","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2006.08.002_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.2005.05856.x","article-title":"Guidelines on oral anticoagulation (warfarin): Third edition\u20142005 update","volume":"132","author":"Baglin","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2006.08.002_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","article-title":"Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy","volume":"77","author":"Makris","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.thromres.2004.04.004","article-title":"Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation","volume":"113","author":"Lubetsky","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2006.08.002_bib14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcp025373","article-title":"Care of patients receiving long-term anticoagulant therapy","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-137-11-200212030-00009","article-title":"Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate","volume":"137","author":"Deveras","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4065\/79.12.1495","article-title":"Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage","volume":"79","author":"Freeman","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tmrv.2006.08.002_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3171\/jns.2003.98.4.0737","article-title":"The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: Preliminary findings","volume":"98","author":"Lin","year":"2003","journal-title":"J Neurosurg"},{"key":"10.1016\/j.tmrv.2006.08.002_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00001721-200307000-00007","article-title":"Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects","volume":"14","author":"Sorensen","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.tmrv.2006.08.002_bib19","article-title":"Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation","author":"Dickneite","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2006.08.002_bib20","first-page":"Abstr 2049","article-title":"Clinical use of protamine for the emergency reversal of anticoagulation with low molecular weight heparin","volume":"3","author":"van Veen","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib21","first-page":"Abstr 2633","article-title":"Successful use of rVIIa (NovoSeven) to reverse enoxaparin (Lovenox) overdose in an adult patient with intracranial bleeding","author":"Lewis","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2003-07-2334","article-title":"Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo","volume":"103","author":"Schick","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2006.08.002_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-2004-831050","article-title":"Recombinant platelet factor 4 for heparin neutralization","volume":"30","author":"Mixon","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00000542-200508000-00005","article-title":"Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass","volume":"103","author":"Stafford-Smith","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tmrv.2006.08.002_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00000542-200402000-00038","article-title":"Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII","volume":"100","author":"Malherbe","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.tmrv.2006.08.002_bib26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1592\/phco.26.4.576","article-title":"Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin","volume":"26","author":"Oh","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tmrv.2006.08.002_bib27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1160\/TH03-09-0605","article-title":"Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers","volume":"91","author":"Wolzt","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0049-3848(00)00397-2","article-title":"Effects of activated prothrombin complex concentrate or recombinant factor VIIa on bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor","volume":"101","author":"Elg","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2006.08.002_bib29","first-page":"182","article-title":"Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models","volume":"25","author":"Diehl","year":"1995","journal-title":"Haemostasis"},{"key":"10.1016\/j.tmrv.2006.08.002_bib30","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity","volume":"2","author":"Aledort","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-0038-1647455","article-title":"The influence of infusions of 1-desamino-8-d-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro","volume":"65","author":"Ibbotson","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-0038-1650299","article-title":"DDAVP reduces bleeding during continued hirudin administration in the rabbit","volume":"75","author":"Bove","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0037-1615162","article-title":"Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig","volume":"80","author":"Dickneite","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib35","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib36","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib37","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2006.08.002_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation","volume":"2","author":"PERSIST investigators","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/107602960100700112","article-title":"Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications","volume":"7","author":"Daud","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0049-3848(00)00368-6","article-title":"Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site","volume":"100","author":"Yu","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.tmrv.2006.08.002_bib41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1160\/TH03-07-0483","article-title":"Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood","volume":"91","author":"Gerotziafas","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0735-1097(03)00653-3","article-title":"The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes","volume":"42","author":"Bijsterveld","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tmrv.2006.08.002_bib43","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1046\/j.1538-7836.2003.00536.x","article-title":"Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux","volume":"1","author":"Lisman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2003.04811.x","article-title":"Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers","volume":"124","author":"Bijsterveld","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2006.08.002_bib45","first-page":"184","article-title":"Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid","volume":"63","author":"Huvers","year":"2005","journal-title":"Neth J Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib46","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.amjmed.2005.04.025","article-title":"Reversal of a potent investigational anticoagulant: Idraparinux with recombinant factor VIIa","volume":"118","author":"Dao","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.tmrv.2006.08.002_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/hc2601.091386","article-title":"Dose-response study of recombinant factor VIIa\/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement","volume":"104","author":"Lee","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.tmrv.2006.08.002_bib48","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0735-1097(03)00478-9","article-title":"Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor\/factor VIIa complex, in patients undergoing elective coronary angioplasty","volume":"41","author":"Moons","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tmrv.2006.08.002_bib49","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/01.CIR.103.21.2555","article-title":"Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects","volume":"103","author":"Friederich","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.tmrv.2006.08.002_bib50","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1055\/s-0037-1614126","article-title":"Blocking the initiation of coagulation by RNA aptamers to factor VIIa","volume":"84","author":"Rusconi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tmrv.2006.08.002_bib51","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1160\/TH04-12-0790","article-title":"Nucleic acid aptamers in therapeutic anticoagulation","volume":"93","author":"Becker","year":"2005","journal-title":"Thromb Haemost"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796306000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796306000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T08:17:50Z","timestamp":1587284270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796306000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0887796306000599"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2006.08.002","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}